|
|
||||||||
Division of Nuclear Medicine, Department of Internal Medicine, Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan
Correspondence: For correspondence or reprints contact: Richard L. Wahl, MD, Division of Nuclear Medicine, Univ. of Michigan Medical Center, 1500 E. Medical Center Dr., B1G412, Ann Arbor, MI 48109-0028.
ABSTRACT
To assess the feasibility and accuracy of positron emission tomography (PET) in the detection of metastatic malignant melanoma, the authors studied 12 patients approximately 1 hr following a 10-mCi injection of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). Scan findings were compared to physical examination, imaging and biopsy results. For intra-abdominal visceral and lymph node metastases, the sensitivity of FDG-PET was 100% (15/15). PET also identified three metastatic foci noted only retrospectively on CT, and two metastatic foci seen only on follow-up CT several months later. Eight additional intense foci of FDG uptake that were seen on PET have not yet been confirmed as tumors. In superficial lymph nodes, PET correctly identified seven of seven metastatic lesions (including three cases involving normal-sized lymph nodes) and correctly predicted the absence of tumor in six of six lymph node regions, for an overall accuracy of 100% (13/13). The sensitivity of the PET technique for detecting small pulmonary lesions was lower than CT but this could be due to respiratory motion or prior cancer treatment. This initial experience demonstrates the feasibility and clinical potential of FDG-PET for the detection of regional and systemically metastatic malignant melanoma, particularly in extra-pulmonary lesions.
This article has been cited by other articles:
![]() |
K. Strobel, R. Dummer, D. B. Husarik, M. Perez Lago, T. F. Hany, and H. C. Steinert High-Risk Melanoma: Accuracy of FDG PET/CT with Added CT Morphologic Information for Detection of Metastases Radiology, August 1, 2007; 244(2): 566 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bastiaannet, O. S. Hoekstra, W. J. G. Oyen, P. L. Jager, T. Wobbes, and H. J. Hoekstra Level of Fluorodeoxyglucose Uptake Predicts Risk for Recurrence in Melanoma Patients Presenting With Lymph Node Metastases Ann. Surg. Oncol., July 1, 2006; 13(7): 919 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Aloia, J. E. Gershenwald, R. H. Andtbacka, M. M. Johnson, C. W. Schacherer, C. S. Ng, J. N. Cormier, J. E. Lee, M. I. Ross, and P. F. Mansfield Utility of Computed Tomography and Magnetic Resonance Imaging Staging Before Completion Lymphadenectomy in Patients With Sentinel Lymph Node-Positive Melanoma J. Clin. Oncol., June 20, 2006; 24(18): 2858 - 2865. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Wagner Fluorodeoxyglucose Positron Emission Tomography for Melanoma Staging: Refining the Indications Ann. Surg. Oncol., April 1, 2006; 13(4): 444 - 446. [Full Text] [PDF] |
||||
![]() |
M. S. Brady, T. Akhurst, K. Spanknebel, S. Hilton, M. Gonen, A. Patel, and S. Larson Utility of Preoperative [(18)]F Fluorodeoxyglucose-Positron Emission Tomography Scanning in High-Risk Melanoma Patients Ann. Surg. Oncol., April 1, 2006; 13(4): 525 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kato, T. Kubota, M. Ikeda, M. Tadokoro, S. Abe, S. Nakano, M. Nishino, H. Kobayashi, and T. Ishigaki Low Efficacy of 18F-FDG PET for Detection of Uveal Malignant Melanoma Compared with 123I-IMP SPECT J. Nucl. Med., March 1, 2006; 47(3): 404 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fuster, S. Chiang, G. Johnson, L. M. Schuchter, H. Zhuang, and A. Alavi Is 18F-FDG PET More Accurate Than Standard Diagnostic Procedures in the Detection of Suspected Recurrent Melanoma? J. Nucl. Med., August 1, 2004; 45(8): 1323 - 1327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Finkelstein, J. A. Carrasquillo, J. M. Hoffman, B. Galen, P. Choyke, D. E. White, S. A. Rosenberg, and R. M. Sherry A Prospective Analysis of Positron Emission Tomography and Conventional Imaging for Detection of Stage IV Metastatic Melanoma in Patients Undergoing Metastasectomy Ann. Surg. Oncol., August 1, 2004; 11(8): 731 - 738. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Wagner Editorial: A Role for FDG-PET in the Surgical Management of Stage IV Melanoma Ann. Surg. Oncol., August 1, 2004; 11(8): 721 - 722. [Full Text] [PDF] |
||||
![]() |
S. W. Fosko, W. Hu, T. F. Cook, and V. J. Lowe Positron Emission Tomography for Basal Cell Carcinoma of the Head and Neck Arch Dermatol, September 1, 2003; 139(9): 1141 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer J. Nucl. Med., May 1, 2003; 44(5): 690 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
G S Mijnhout, O S Hoekstra, A van Lingen, P J van Diest, H J Ader, A A Lammertsma, R Pijpers, S Meijer, and G J J Teule How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma J. Clin. Pathol., April 1, 2003; 56(4): 283 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Ryu, M.-H. Kim, S.-C. Choi, C.-W. Choi, and K.-H. Lee Detection of Early Recurrence with 18F-FDG PET in Patients with Cervical Cancer J. Nucl. Med., March 1, 2003; 44(3): 347 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Jeong, J.-K. Chung, Y. K. Kim, C. Y. Kim, D. G. Kim, J. M. Jeong, D. S. Lee, H. W. Jung, and M. C. Lee Usefulness of Whole-Body 18F-FDG PET in Patients with Suspected Metastatic Brain Tumors J. Nucl. Med., November 1, 2002; 43(11): 1432 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Swetter, L. A. Carroll, D. L. Johnson, and G. M. Segall Positron Emission Tomography Is Superior to Computed Tomography for Metastatic Detection in Melanoma Patients Ann. Surg. Oncol., August 1, 2002; 9(7): 646 - 653. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Belhocine, G. Pierard, M. de Labrassinne, T. Lahaye, and P. Rigo Staging of Regional Nodes in AJCC Stage I and II Melanoma: 18FDG PET Imaging versus Sentinel Node Detection Oncologist, August 1, 2002; 7(4): 271 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al. Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma* J. Nucl. Med., June 1, 2002; 43(6): 811 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.J.R. Dalrymple-Hay, P.D. Rome, C. Kennedy, M. Fulham, and B.C. McCaughan Pulmonary metastatic melanoma -- the survival benefit associated with positron emission tomography scanning Eur. J. Cardiothorac. Surg., April 1, 2002; 21(4): 611 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Williams, C. Cousins, W. P. Soutter, M. Mubashar, A. M. Peters, R. Dina, F. Fuchsel, G. A. McIndoe, and N. M. deSouza Detection of Pelvic Lymph Node Metastases in Gynecologic Malignancy: A Comparison of CT, MR Imaging, and Positron Emission Tomography Am. J. Roentgenol., August 1, 2001; 177(2): 343 - 348. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.M. Acland, C. Healy, E. Calonje, M. O'Doherty, T. Nunan, C. Page, E. Higgins, and R. Russell-Jones Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Micrometastases of Primary Cutaneous Malignant Melanoma J. Clin. Oncol., May 15, 2001; 19(10): 2674 - 2678. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF] |
||||
![]() |
A. Dimitrakopoulou-Strauss, L. G. Strauss, and C. Burger Quantitative PET Studies in Pretreated Melanoma Patients: A Comparison of 6-[18F]Fluoro-L-Dopa with 18F-FDG and 15O-Water Using Compartment and Noncompartment Analysis J. Nucl. Med., February 1, 2001; 42(2): 248 - 256. [Abstract] [Full Text] |
||||
![]() |
Y. Anzai, S. Minoshima, G. T. Wolf, and R. L. Wahl Head and Neck Cancer: Detection of Recurrence with Three-dimensional Principal Components Analysis at Dynamic FDG PET Radiology, July 1, 1999; 212(1): 285 - 290. [Abstract] [Full Text] |
||||
![]() |
J. D. Wagner, D. Schauwecker, D. Davidson, J. J. Coleman III, S. Saxman, G. Hutchins, C. Love, and J. T. Hayes Prospective Study of Fluorodeoxyglucose–Positron Emission Tomography Imaging of Lymph Node Basins in Melanoma Patients Undergoing Sentinel Node Biopsy J. Clin. Oncol., May 1, 1999; 17(5): 1508 - 1508. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Strauss Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology Oncologist, December 1, 1997; 2(6): 381 - 388. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |